1.A Case of Lichenoid Drug Eruption Associated with Imatinib Mesylate.
Jung Eun SEOL ; So Hee PARK ; Do Hyeong KIM ; Hyojin KIM ; Jeong Nan KANG
Korean Journal of Dermatology 2017;55(9):621-622
No abstract available.
Drug Eruptions*
;
Imatinib Mesylate*
2.Exacerbation of Psoriasis after Imatinib Mesylate Treatment.
Joon Ho SHIM ; Seung Hwan OH ; Ji Young JUN ; Jun Hwan KIM ; Hae Young PARK ; Ji Hye PARK ; Dong Youn LEE
Annals of Dermatology 2016;28(3):409-411
No abstract available.
Imatinib Mesylate*
;
Psoriasis*
3.Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate.
Hyo Sang SONG ; Hee Young KANG
Annals of Dermatology 2014;26(4):532-533
No abstract available.
Hyperpigmentation*
;
Nose*
;
Palate*
;
Imatinib Mesylate
4.Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.
Eunjung YIM ; Ho Jung AN ; Uiju CHO ; Youngwoo KIM ; Seung Hoon KIM ; Yeon Geun CHOI ; Byoung Yong SHIM
The Korean Journal of Internal Medicine 2018;33(2):432-434
No abstract available.
Gastrointestinal Stromal Tumors*
;
Imatinib Mesylate*
5.Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
Dae Sik KIM ; Sunki LEE ; Chul Won CHOI
The Korean Journal of Internal Medicine 2018;33(3):642-644
No abstract available.
Eosinophils*
;
Hypereosinophilic Syndrome*
;
Imatinib Mesylate*
6.Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib.
Min Kyung LEE ; Won Joo KWON ; Eun Byul CHO ; Eun Joo PARK ; Kwang Ho KIM ; Kwang Joong KIM
Annals of Dermatology 2015;27(5):641-643
No abstract available.
Erythema Multiforme*
;
Erythema*
;
Recurrence*
;
Imatinib Mesylate
7.A rare case of systemic mastocytosis in a 72-year-old female with gastrointestinal bleeding.
Nathania Maxene P. Sianghio ; Maria Claudia Chavez ; Roli June Chavez ; Roberto De Guzman
Philippine Journal of Internal Medicine 2024;62(3):177-182
Mastocytosis is a rare disorder that results from the clonal proliferation of abnormal mast cells which accumulates in the skin and extracutaneous organs. Its prevalence is estimated at 1 in 10,000 persons. Cutaneous mastocytosis occurs in less than 5% of adults while adult-onset mastocytosis is suggestive of systemic progression. Involvement of the gastrointestinal tract occurs in 14-85% of patients diagnosed with systemic mastocytosis. This case involves a 72-year-old female previously diagnosed with cutaneous mastocytosis who presented with gastrointestinal symptoms fifteen years later. Workups done included CT scan, colonoscopy, and bone marrow aspiration. Colonic and bone marrow tissue samples revealed eosinophilia with CD117 positivity. The patient was started on therapy with imatinib. No recurrence of hematochezia was observed on follow-up.
Human ; Female ; Aged: 65-79 Yrs Old ; Mastocytosis, Systemic ; Imatinib ; Imatinib Mesylate
8.Cancer Metabolism: Strategic Diversion from Targeting Cancer Drivers to Targeting Cancer Suppliers.
Biomolecules & Therapeutics 2015;23(2):99-109
Drug development groups are close to discovering another pot of gold-a therapeutic target-similar to the success of imatinib (Gleevec) in the field of cancer biology. Modern molecular biology has improved cancer therapy through the identification of more pharmaceutically viable targets, and yet major problems and risks associated with late-phase cancer therapy remain. Presently, a growing number of reports have initiated a discussion about the benefits of metabolic regulation in cancers. The Warburg effect, a great discovery approximately 70 years ago, addresses the "universality" of cancer characteristics. For instance, most cancer cells prefer aerobic glycolysis instead of mitochondrial respiration. Recently, cancer metabolism has been explained not only by metabolites but also through modern molecular and chemical biological techniques. Scientists are seeking context-dependent universality among cancer types according to metabolic and enzymatic pathway signatures. This review presents current cancer metabolism studies and discusses future directions in cancer therapy targeting bio-energetics, bio-anabolism, and autophagy, emphasizing the important contribution of cancer metabolism in cancer therapy.
Autophagy
;
Biology
;
Glycolysis
;
Metabolism*
;
Molecular Biology
;
Respiration
;
Imatinib Mesylate
9.A High Risk Group in the Modified National Institutes of Health Consensus Criteria for the Gastrointestinal Stromal Tumor: A Clear Indication of the Adjuvant Imatinib.
Intestinal Research 2014;12(3):176-177
No abstract available.
Consensus*
;
Gastrointestinal Stromal Tumors*
;
Imatinib Mesylate
;
National Institutes of Health (U.S.)*
10.Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate.
Hyung Ok KIM ; Bo In LEE ; Jun Young LEE ; Young Min PARK
Annals of Dermatology 2013;25(4):526-528
No abstract available.
Benzamides
;
Mesylates*
;
Nails, Malformed*
;
Piperazines
;
Pyrimidines
;
Imatinib Mesylate
Result Analysis
Print
Save
E-mail